Core Viewpoint - The article discusses the significant role of preoperative exercise in preventing colorectal cancer liver metastasis (CRLM) by enhancing anti-tumor immune responses through Kupffer cells [3][6]. Group 1: Colorectal Cancer and Liver Metastasis - Colorectal cancer (CRC) is the third most common cancer globally and the second leading cause of cancer-related deaths, with approximately 50% of patients developing liver metastasis [2]. - Surgical resection of liver metastases can improve overall survival rates by 15% to 20%, but 50% to 60% of patients experience recurrence due to undetected micro-metastases or tumor cell dissemination [2][5]. Group 2: Impact of Surgical Stress - Surgical-induced immune dysregulation alters the host-tumor immune environment, potentially promoting tumor recurrence [2]. - Postoperative systemic and local inflammation is directly associated with poorer cancer prognosis, although the mechanisms remain poorly understood [2]. Group 3: Research Findings - A study published by Zhang Hongji's team indicates that preoperative exercise (PEx) for four weeks can induce anti-tumor Kupffer cells, limiting tumor growth in a mouse model of surgical stress-promoted liver metastasis [3][6]. - Preoperative exercise enhances the release of cytotoxic cytokines from Kupffer cells and increases the recruitment and activation of CD8+ T cells via the CXCL9-CXCR3 signaling axis [5][6]. - Elevated levels of CXCL9 were observed in the serum of both mice and patients post-exercise, with Kupffer cells identified as the primary source [5][6]. Group 4: Implications of the Study - The study suggests that preoperative exercise could serve as a non-invasive strategy to reduce cancer metastasis and recurrence rates, providing potential targets for exercise mimetic therapies [8].

Core Viewpoint - The study identifies a chemotherapy-induced PTGER3+ cancer-associated fibroblast (CAF) subgroup characterized by enhanced lipid oxidation, termed lipo-CAF, which promotes CD8+ T-cell activation and cytotoxicity, thereby enhancing anti-tumor immunity and therapeutic response [2][3][9] Group 1: Mechanism and Findings - The research reveals a previously unrecognized metabolic adaptation mechanism in CAFs that supports CD8+ T-cell immunity, highlighting the role of lipid oxidation driven by CAFs in regulating CD8+ T-cell PTEN signaling as a potential pathway to enhance chemotherapy and immunotherapy efficacy [3][8] - Lipo-CAF specifically secretes lipid oxidation products like 11-HETE, which acts as an endogenous lipid ligand on CD8+ T-cells, inhibiting PTEN function and enhancing T-cell cytotoxicity and anti-tumor immune function [6][9] - The study emphasizes that the metabolic reprogramming of CAFs under chemotherapy conditions fine-tunes T-cell function, providing a theoretical basis for understanding the synergy between chemotherapy and anti-tumor immune responses [8][9] Group 2: Clinical Implications - A higher proportion of treatment-induced PTGER3+ CAFs is associated with improved therapeutic responses and better patient prognosis [2] - The findings suggest that 11-HETE supplementation could enhance the efficacy of chemotherapy and immunotherapy, indicating a potential new intervention strategy based on tumor microenvironment metabolic characteristics [9]

Core Viewpoint - Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of only 12-18 months post-diagnosis, and current treatments have limited efficacy in extending life expectancy [3] Group 1: Research Findings - A recent study published in Nature Cell Biology indicates that inhibiting lactate transport derived from tumor-associated macrophages (TAM) can restore cGAS-STING signaling and enhance antitumor immunity in glioblastoma [4] - The research team discovered that lactate is transported from TAM to glioblastoma stem cells (GSC) via MCT4-MCT1, promoting GSC proliferation and inducing lactylation modification of the non-homologous end joining protein KU70 at lysine 317 (K317), which inhibits cGAS-STING signaling and remodels the immunosuppressive tumor microenvironment [7] - Overall, the study reveals that lactate and lactylation modifications produced by TAM are key regulatory factors in maintaining the immunosuppressive tumor microenvironment in GSC, opening new avenues for combination therapies in glioblastoma [9]

Core Viewpoint - CAR-T cell therapy has shown remarkable clinical efficacy in hematological cancers, but approximately 30%-50% of patients experience disease relapse within one year post-treatment, highlighting the need for improved T cell persistence strategies [2][5]. Group 1: CAR-T Cell Therapy Challenges - Despite the success of CAR-T cell therapy, it is associated with severe toxicities, including cytokine release syndrome and neurotoxicity [2]. - The persistence of T cells is crucial for the efficacy and long-term remission of CAR-T cell therapy, influenced by factors such as the percentage of stem cell-like memory T cells and T cell proliferation capacity [2][5]. Group 2: New Research Developments - A study published by a team from the University of Southern California introduced a novel CAR structure driven by the ZAP327 signaling domain, which significantly reduces cytokine release and T cell exhaustion while generating robust and long-lasting antitumor immunity in mouse models [3][5]. - The ZAP327-driven CAR-T cells demonstrated superior therapeutic antitumor activity compared to traditional CAR-T cells, particularly in low antigen-expressing tumor models, leading to extended survival in mouse experiments [5][8]. Group 3: Mechanisms of Action - The ZAP327 domain modulates TCR signaling, increases the pool of stem cell-like memory T cells, and exhibits metabolic characteristics associated with memory T cells through oxidative phosphorylation pathways [6][8]. - The study emphasizes the potential of ZAP327-driven CAR-T cells to overcome the limitations of current CAR-T therapies and enhance T cell responses against solid tumors [8].

Core Viewpoint - Dietary restriction (DR) can extend the lifespan of mammals and delay age-related diseases, including cancer, through mechanisms that are not yet fully understood [1]. Group 1: Research Findings - A study published in Nature Metabolism indicates that dietary restriction leads to metabolic changes in ketone bodies, specifically increasing β-hydroxybutyrate (βOHB), which reprograms the fate and function of CD8+ T cells in the tumor microenvironment, enhancing anti-tumor immunity and responses to immunotherapy [1]. - In experiments, mice subjected to a 50% dietary restriction showed a significant slowdown in tumor growth and a survival extension of 30%-80% compared to those with free access to food [4]. - The anti-cancer effects of dietary restriction were found to be dependent on the immune system, particularly CD8+ T cells, as the effects disappeared in T cell-deficient mice [4]. Group 2: Mechanism of Action - CD8+ T cells, known as "killer cells," are responsible for identifying and destroying cancer cells, but often become "exhausted" in the tumor microenvironment [6]. - Dietary restriction promotes the expansion of effector T cell subsets with stronger anti-cancer capabilities while limiting the accumulation of terminally exhausted T cells [7]. - The mechanism behind this transformation is linked to ketone metabolism, where increased βOHB enhances mitochondrial function and energy metabolism in CD8+ T cells, thereby boosting their anti-cancer capabilities [8]. Group 3: Implications for Cancer Therapy - The study found that dietary restriction can synergize with existing cancer immunotherapies, such as PD-1 monoclonal antibodies, significantly improving treatment outcomes and even leading to complete tumor regression in some melanoma mouse models [9]. - The research suggests that dietary interventions could be a simple and effective strategy to enhance the efficacy of cancer immunotherapy [11]. - Given the challenges of implementing strict dietary restrictions in clinical settings, alternative approaches such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) may simulate the metabolic effects of dietary restriction [11].

Core Viewpoint - The research highlights the potential of Vitamin B6, specifically its active form pyridoxal phosphate (PLP), in enhancing the stem-like characteristics and antitumor abilities of CD8+ T cells, suggesting its clinical application in cancer immunotherapy [2][10]. Group 1: Mechanism and Findings - Tumor-infiltrating lymphocytes (TILs) often exhibit dysfunction but can display stem-like behavior through unclear mechanisms [6]. - The study found that Vitamin B6 or PLP treatment enhances the persistence and stem-like phenotype of CD8+ T cells, improving their ability to eliminate tumors [6][8]. - PLP maintains T cell functionality by directly binding to and inhibiting p70S6 kinase (p70S6K), which in turn affects the phosphorylation of BACH2, promoting stem cell gene expression while suppressing exhaustion gene expression [6][11]. Group 2: Clinical Implications - In preclinical tumor models, PLP treatment improved the efficacy of anti-PD-1 monoclonal antibody therapy [7]. - The research underscores the clinical potential of strategies that enhance T cell functionality through Vitamin B6/PLP in cancer immunotherapy [10].

Core Insights - The study published by the team led by Academician Dong Chen from Westlake University in the journal Science highlights the role of Ms4a7 expression in cDC1 cells in promoting cross-activation of CD8+ T cells against tumors [2] - The absence of Ms4a7 in cDC1 cells impairs the specific CD8+ T cell response targeting tumors and weakens T cell immunity during bacterial and viral infections [2][4] - Human data analysis indicates that infiltration of MS4A7-expressing cDC1 cells is associated with enhanced CD8+ T cell tumor immunity and improved patient survival rates [2][4] Group 1 - cDC1 cells capture antigens in peripheral tissues and migrate to draining lymph nodes (dLN) to initiate antigen-specific CD8+ T cell immune responses [3] - The study found that Ms4a7 expression is upregulated in cDC1 cells upon tumor antigen uptake or exposure to external stimuli, which is essential for their cross-presentation capability [4] - Ms4a7 is located in antigen-processing vesicles, facilitating steps in the antigen presentation process without altering upstream uptake or degradation [6] Group 2 - The research reveals how tumor microenvironment signals regulate Ms4a7 expression in cDC1, enhancing their cross-presentation ability and CD8+ T cell activation [6] - In human cancers, the expression of MS4A7 correlates with robust interactions between cDC1 and T cells, leading to favorable clinical outcomes [6]

Core Insights - The study published in Nature Immunology reveals that chemotherapy-induced CA-repeat DNA fragments in breast cancer can trigger antitumor immune responses [3][4]. - The research highlights the relationship between genomic instability and immune regulation, emphasizing the therapeutic potential of CA-rich DNA in enhancing antitumor immunity [7]. Group 1 - The research team demonstrated that in tumors with low expression of MSH2, DNA fragments rich in CA, generated by DNA-damaging chemotherapy, preferentially bind with cGAS, leading to the formation of biomolecular condensates in the cytoplasm and triggering antitumor immune responses [7]. - In contrast, DNA fragments lacking CA released from tumors with high MSH2 expression activate AIM2, resulting in immune suppression through the upregulation of PD-L1 and IDO [7]. - The study found that the increase in CA-rich DNA fragments post-chemotherapy correlates with a rise in tumor antigen-responsive T cells and better chemotherapy responses [7]. Group 2 - The injection of CA-rich DNA fragments into tumors enhances antitumor immunity in PyMT allograft tumors [7]. - Different tumor DNA fragments can elicit opposing immune responses based on their preference for different sensors [7].

Core Viewpoint - The research highlights the immune-regulating properties of Zeaxanthin, a nutrient found in leafy vegetables and corn, which enhances CD8+ T cell function and improves anti-tumor immunity, indicating its potential as a dietary supplement in cancer therapy [3][10]. Group 1: Research Findings - Zeaxanthin is identified as an immune modulator that enhances the function of CD8+ effector T cells, thereby increasing anti-tumor immunity [3][10]. - Oral supplementation of Zeaxanthin improves the efficacy of anti-PD-1 immune checkpoint inhibitors and enhances the cytotoxicity of TCR-engineered CD8+ T cells against tumor cells [9][10]. - The study utilized a "blood nutrient" library to identify dietary nutrients that influence CD8+ T cell function, revealing that trans-18:1 fatty acid (TVA) also promotes CD8+ T cell activity and response to immunotherapy [6][8]. Group 2: Mechanisms of Action - Zeaxanthin enhances T cell receptor (TCR) signaling on CD8+ T cells, improving their functional response [9][10]. - The research indicates that the structural isomer Lutein does not exhibit the same immune-enhancing effects as Zeaxanthin, underscoring the unique properties of Zeaxanthin [8][10]. - The findings suggest that dietary components can play a significant role in modulating immune responses, particularly in the context of cancer treatment [5][12].

Core Viewpoint - The source of dietary fat significantly influences anti-tumor immunity in obese individuals, with animal fats impairing immune response and promoting tumor growth, while plant fats do not have this negative effect [5][7][9]. Group 1: Research Findings - A study published in Nature Metabolism indicates that high-fat diets based on animal fats (lard, beef tallow, or butter) weaken anti-tumor immunity in obese mice and accelerate tumor growth [5][7]. - In contrast, high-fat diets based on plant oils (coconut oil, palm oil, or olive oil) do not exhibit this detrimental effect, with palm oil even enhancing anti-tumor immunity and slowing tumor growth in obese mice [5][7][9]. - The research highlights that the metabolic byproducts of animal fats, particularly long-chain acylcarnitines, strongly inhibit NK and CTL cells, leading to impaired immune function [9]. Group 2: Implications for Cancer Treatment - The findings suggest that dietary modifications, such as replacing animal fats with plant oils, could be beneficial for obese cancer patients undergoing treatment, potentially lowering their cancer risk [5][6][9]. - The study emphasizes the importance of dietary fat composition in maintaining a healthy immune system and improving treatment outcomes for obese individuals with cancer [9].